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Childhood Immune Thrombocytopenia—Who Will
Spontaneously Recover?
Joanne Yacobovich,a Shoshana Revel-Vilk,b and Hannah TamaryaAlthough the majority of children with immune thrombocytopenia (ITP) have a short duration0037-1963
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Seminarsof the disease, the very rare but significant complications of the disease often cause fear and
anxiety among families of children with ITP. Added to the reduced quality of life (QoL) of those
children are restrictions imposed on daily activities to avoid trauma. Treatment decisions in
chronic ITP and especially regarding splenectomy are hampered by the inability to predict
when recovery will take place. Identification of predictors of recovery would be beneficial for
improving treatment decisions and QoL of both children and families. This literature review
focuses on clinical parameters and emerging genetic biomarkers for prediction of duration of
childhood ITP. Higher recovery rates were found among infants with newly diagnosed ITP. In
contrast onset of the disease at adolescence was associated with worse recovery rates. Six
clinical features were found to be associated with short duration of disease; the most
prominent ones were abrupt onset of bleeding symptoms (o2 weeks) and age at onsetr10
years. Two genetic biomarkers have been suggested as predictors of chronic disease:
overexpression of vanin-1 (VNN-1), an oxidative stress sensor, and the Q63R missense variant
of the gene encoding the cannabinoid receptor type 2. To be clinically useful each of those
predictors requires further validation in larger studies. Genetic biomarkers will potentially offer
direct and early prognosis estimation.
Semin Hematol 50:S71–S74. C 2013 Published by Elsevier Inc.Open access under CC BY-NC-ND license.C
hildhood immune thrombocytopenia (ITP) is
usually a self-limited disorder lasting for a few
weeks or months, but in approximately 25%–
30% of the children, the condition becomes chronic.1–4
In chronic ITP spontaneous recovery occurs within
5 years of diagnosis in about 50% of children5 and in
few children even many years later.6 Confronted with a
child with newly diagnosed ITP the physician cannot
determine if the child has a self-limited disease or will
have long-term chronic disorder. Similarly while treating
a child with chronic ITP the physician does not know if
and when will the child recover.
Although childhood ITP is considered to be a
benign disease it may rarely result in significantblished by Elsevier Inc.
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Open access under CC BY-NC-ND license.morbidity and mortality.7,8 Therefore, families of
children with ITP often live with fear and anxiety.
Furthermore, restrictions imposed on daily activities
to avoid trauma contribute significantly to children’s
already a reduced quality of life (QoL). Negative
impact of the disease on QoL of the child and his
family has been documented.9,10 Identification of
predictors of early recovery would be beneficial for
reducing stress and improving QoL for both children
and families.
Management of children with chronic ITP remains
controversial. Splenectomy induces complete and sus-
tained remission in more than 75% of children with
chronic ITP.11 However, the high rate of spontaneous
remissions, possible failure to achieve durable remis-
sion and the life-long risk of overwhelming septicemia
following splenectomy suggest that this procedure
should not be undertaken lightly. Additionally, new
drug therapies have emerged, including rituximab12
and most recently thrombopoiesis-stimulating agents
that may influence therapeutic directions.13 Defining
predictors of recovery from chronic childhood ITP will
eventually improve treatment decisions.
This literature review focuses on clinical parame-
ters and on emerging genetic biomarkers for pre-
diction of duration of childhood ITP.p S71–S74 S71
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NEWLY DIAGNOSED ITP
Although traditionally chronic ITP was defined
as lasting for more than 6 months, based on high
rates of recovery of children with ITP occurring
between 7–12 months from diagnosis2,14 the Interna-
tional Working Group suggested that chronic
ITP should be defined as thrombocytopenia (platelet
counto100  109/L) lasting longer than 12 months.15
Nevertheless, all studies cited herein used the tradi-
tional more than 6 months definition of chronic ITP.
Young age at diagnosis and initial therapy with
intravenous immunoglobulin (IVIG) have been sug-
gested to predict short duration of ITP. Predictive
scores for early recovery have also been developed.
Recently, two genetic biomarkers were identified to
be associated with long duration of the disease in
children.Table 1. Nordic Prediction Score for Brief
Course of ITP
Clinical Feature Prediction
Weight
Abrupt onset 5
Age at diagnosiso10 3AGE AT DIAGNOSIS
Short duration of the disease was reported in the
majority (70%–75%) of children with ITP; however,
infants and adolescent seem to have different chan-
ces of recovery. The Intercontinental Cooperative
ITP Study Group registry I (ICIS I, 1997–2000)
followed children with newly diagnosed ITP world-
wide in order to study the natural history of ITP. Of
2,540 children, 203 were infants (7.6%). The recov-
ery rate was 77%, which is significantly higher
compared to 68.6% in older children (Po.0001).7
Donato et al studied childhood ITP in Argentina and
also suggested a high recovery rate of 89.8% among
275 infants with ITP.14
In contrast, onset of the disease in adolescence
was found to be associated with recovery rates of
only 32%–53%, which is a significantly worse prog-
nosis compared to younger children.7,14,16 Of 2,540
children in ICIS I, 311 were age 10–16 years and
their recovery rate was only 53% compared to 72%
observed in children between 1 and 10 years of age.7
Donato et al found a 49% recovery rate among 210
children aged 9–18 years at diagnosis compared to
71.3% for children 1–8 years of age at diagnosis.14
Lowe and Buchanan retrospectively reviewed chil-
dren diagnosed with ITP between 10–18 years of age
and found only a 32% recovery rate.16years
Postinfection 2
Platelet counto5 x 109/L 2
Wet purpura 1
Male gender 1
Abrupt onset: symptoms foro14 days; postinfection:
infection or vaccinationo1 month prior to onset; wet
purpura: purpura with oozing, mucosal bleeding; High
score ¼ 10–14; Intermediate score ¼ 5–9; Low score ¼ 0–
4; Adapted from Edslev et al.18TYPE OF INITIAL THERAPY
Does initial ITP therapy affect disease duration?
This subject was studied in a retrospective manner
using the ICIS I data.17 Matched-pairs analysis of the
ICIS I data identified 449 children not recovering
after 6 months, who were then compared to
matched children with adequate platelet counts.Children initially treated with IVIG were more likely
to have a normal platelet count 6 months after
diagnosis than children receiving no therapy or
corticosteroids.17 Our retrospective study of 472
children with newly diagnosed ITP from two pedia-
tric hematology centers in Israel suggested no differ-
ence in prognosis between children who were
initially treated with IVIG, corticosteroids, or obser-
vation only (unpublished data). The association
between initial therapy and resolution of ITP in
children should be further studied.CLINICAL PREDICTION SCORE
A prospective study designed to identify predic-
tors for short duration of disease in children with
newly diagnosed childhood ITP was performed by
the Nordic group.18 Between the years 1998–2000,
409 newly diagnosed children with ITP were
recruited from 98 pediatric centers in the Nordic
countries. Six clinical features significantly associ-
ated with short duration of the disease (o3 months)
were identified: abrupt onset of the disease (o2
weeks duration of bleeding symptoms), age at
onset ofr10 years, preceding infection, platelet
counto5  109/L at diagnosis, wet purpura, and
male gender. A scoring system was designed whereby
each parameter was awarded a numerical values
based on the odds ratio for brief disease. Abrupt
onset of the disease and age at onsetr10 years had
the highest odds ratio. A high Nordic score (10–14
points) predicted brief and uneventful course of the
disease, while a low score (0–4 points) predicted
prolonged course (see Table 1). Indeed, the majority
of children with a high score (78%) had a brief
course of the disease, while only 22% of the children
with a low score had a short course of the disease.
Danto et al applying the Nordic score to children
older than 12 months at the time of diagnosis
Spontaneous recovery in childhood ITP S73suggested that it had a predictive value for recovery
of ITP at 6 months following diagnosis.14 We ana-
lyzed the application of the Nordic score in 472
children with newly diagnosed ITP in Israel and
found that of the six variables, two [short duration of
the disease (o 2 weeks) and young age at diagnosis
(r 10 years of age)] were the strongest predictive
parameters for remission at 3, 6, and 12 months
following diagnosis (unpublished data). More studies
are indicated to validate the predictive scores and to
evaluate the benefit of their use to reduce anxiety
and thereby improve QoL in children with ITP and
their parents.GENETIC BIOMARKERS
Primary chronic ITP is a complex autoimmune
disorder with both platelet destruction and immune
T-cell dysregulation.19 Several studies identified
abnormal gene polymorphisms associated with
T-cell activation in patients with chronic ITP.20–22
Zhang et al compared the molecular mechanisms
of chronic and acute ITP in 63 children with chronic
ITP.23 Gene expression analysis of whole blood
revealed that oxidative stress-related pathways were
among the most significant chronic ITP-associated
pathways. Overexpression of vanin-1 (VNN-1), an
oxidative stress sensor, was strongly associated with
progression to chronic disease.23 This study, in
addition to implicating oxidative stress pathways in
the pathogenesis of chronic childhood ITP, offered
an early prognostic estimation. If confirmed by larger
studies determination of VNN-1 expression may be a
useful predictor of disease duration.
The endocannabinoid system is involved in
immune regulation by suppressing cell activation,
modulating Th1 and Th2 balance, and inhibiting pro-
inflammatory cytokine production.24,25 T cells, as
well as all other cellular components of the immune
system, express cannabinoid receptors type 1 and 2
(CB1 and CB2). CB2 is encoded by the CNR2 gene,
and is expressed on immune cells, including T
lymphocytes, B cells, macrophages, and neutrophils.
Rossi et al recently suggested that the CNR2 gene
missense variant (Q63R) was significantly associated
with childhood chronic ITP.26 Further prospective
studies are required to address the prognostic value
of this polymorphism.PREDICTORS FOR RECOVERY FROM
CHRONIC ITP
Several retrospective studies explored the rate of
spontaneous recovery of chronic ITP. Almost all
studies evaluating rate of spontaneous remission in
children with chronic ITP were small retrospective
analyses and they originated from a variety of differentcountries,14,27–32 with only a few including more than
100 patients.14,31 Overall remission rates were 33%–
67% with a follow-up period of 0.7–8.6 years. Donato
et al followed 325 non-splenectomized children with
chronic ITP over a median period of 4 years (range, 6
months–1 years) and found a remission rate of 33%.14
Age at presentation was identified as a prognostic
factor: only 21% of children who were49 years of
age at diagnosis achieved remission, compared with
37.7% for thoseo9 years at diagnosis. Bansal et al
studied 270 children with chronic ITP in India for
0.5–14 years (median, 2.5 years) and found a 51%
remission rated for children less than 8 years at
diagnosis and 34% for those older than 8 years.31 In
this study, female gender was also found to be a
predictor for remission.
To date only one prospective study following 86
children with chronic ITP over 5 years has been
published.5 Two years from diagnosis, 38% of
patients with chronic ITP were in remission, while
at 5 years following diagnosis 48% of patients were
in remission. Spontaneous recovery occurred at a
higher rate during the first 2 years following diag-
nosis and thereafter remission rates were declining.
Analysis of predictors of early recovery within 2 years
from diagnosis suggested that most children with
early recovery from chronic ITP were young (age
0–5 years) at the time of diagnosis and had abrupt
symptom onset.SUMMARY
Defining predictors of recovery of childhood ITP
will improve treatment strategy and reduce patients
and parents’ anxiety. Review of the literature suggest
several predictors of recovery: (1) infants have a
better chance of having a short duration of the
disease while adolescents have higher chances for
chronic disease; (2) six clinical parameters emerge as
associated with a short duration of the disease, with
abrupt disease onset disease and age at onsetr10
years being the most significant; (3) young age at
onset of the disease may also be associated with
better chances of recovery from chronic ITP; (4) two
genetic biomarkers of childhood chronic ITP (VNN-1
and Q63R missense variant of the gene encoding
CB2) have so far been identified. Each of the
predictors listed herein requires further validation
in larger studies. Genetic biomarkers may prove to
be useful for direct and early prognosis estimation.
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